310 related articles for article (PubMed ID: 32335553)
21. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
Malczewska A; Kos-Kudła B; Kidd M; Drozdov I; Bodei L; Matar S; Oberg K; Modlin IM
Adv Med Sci; 2020 Mar; 65(1):18-29. PubMed ID: 31841822
[TBL] [Abstract][Full Text] [Related]
22. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
23. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
24. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
[TBL] [Abstract][Full Text] [Related]
25. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Malczewska A; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):895-906. PubMed ID: 31838581
[TBL] [Abstract][Full Text] [Related]
26. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy.
Modlin IM; Kidd M; Frilling A; Falconi M; Filosso PL; Malczewska A; Kitz A
Ann Surg; 2021 Sep; 274(3):481-490. PubMed ID: 34183517
[TBL] [Abstract][Full Text] [Related]
27. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.
Malczewska A; Witkowska M; Makulik K; Bocian A; Walter A; Pilch-Kowalczyk J; Zajęcki W; Bodei L; Oberg KE; Kos-Kudła B
Endocr Connect; 2019 Mar; 8(4):442-53. PubMed ID: 30865931
[TBL] [Abstract][Full Text] [Related]
28. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
29. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
30. Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease.
Malczewska A; Bodei L; Kidd M; Modlin IM
J Clin Endocrinol Metab; 2019 Mar; 104(3):867-872. PubMed ID: 30358858
[TBL] [Abstract][Full Text] [Related]
31. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
32. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.
van Treijen MJC; Korse CM; van Leeuwaarde RS; Saveur LJ; Vriens MR; Verbeek WHM; Tesselaar MET; Valk GD
Front Endocrinol (Lausanne); 2018; 9():740. PubMed ID: 30564197
[No Abstract] [Full Text] [Related]
33. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis.
Kidd M; Drozdov IA; Matar S; Gurunlian N; Ferranti NJ; Malczewska A; Bennett P; Bodei L; Modlin IM
PLoS One; 2019; 14(6):e0218592. PubMed ID: 31247038
[TBL] [Abstract][Full Text] [Related]
34. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
35. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).
Modlin IM; Kidd M; Oberg K; Falconi M; Filosso PL; Frilling A; Malczewska A; Salem R; Toumpanakis C; Laskaratos FM; Partelli S; Roffinella M; von Arx C; Kudla BK; Bodei L; Drozdov IA; Kitz A
Ann Surg Oncol; 2021 Nov; 28(12):7506-7517. PubMed ID: 34008138
[TBL] [Abstract][Full Text] [Related]
36. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
Panzuto F; Severi C; Cannizzaro R; Falconi M; Angeletti S; Pasquali A; Corleto VD; Annibale B; Buonadonna A; Pederzoli P; Delle Fave G
J Endocrinol Invest; 2004 Jan; 27(1):6-11. PubMed ID: 15053236
[TBL] [Abstract][Full Text] [Related]
37. Octreotide suppression test in diagnosing and predicting the outcome of therapy in patients with neuroendocrine tumors. Preliminary report.
Kos-Kudła B; Zemczak A; Foltyn W; Marek B; Strzelczyk J; Telega A; Zajecki W; Legaszewski T; Jurecka-Lubieniecka B
Endokrynol Pol; 2007; 58(2):123-9. PubMed ID: 17578828
[TBL] [Abstract][Full Text] [Related]
38. Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors.
Partelli S; Andreasi V; Muffatti F; Schiavo Lena M; Falconi M
Ann Surg Oncol; 2020 Oct; 27(10):3928-3936. PubMed ID: 32253675
[TBL] [Abstract][Full Text] [Related]
39. Limitations of Chromogranin A in clinical practice.
Marotta V; Nuzzo V; Ferrara T; Zuccoli A; Masone M; Nocerino L; Del Prete M; Marciello F; Ramundo V; Lombardi G; Vitale M; Colao A; Faggiano A
Biomarkers; 2012 Mar; 17(2):186-91. PubMed ID: 22303881
[TBL] [Abstract][Full Text] [Related]
40. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of
Bodei L; Raj N; Do RK; Mauguen A; Krebs S; Reidy-Lagunes D; Schöder H
J Nucl Med; 2023 Apr; 64(4):567-573. PubMed ID: 36396457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
